Importance of ELABELA in the differential diagnosis of benign and malignant lesions of the thyroid gland

Abstract

Objective: This study investigated whether ELABELA plays a role in the differential diagnosis of benign and malignant lesions of the thyroid gland. Subjects and methods: Of the 87 patients included in the study, 12 had undergone surgery for benign thyroid diseases, 30 had papillary thyroid cancer without invasion and/or lymph node metastasis in the surrounding tissues in the pathology report, and 45 had papillary thyroid cancer with invasion and/or lymph node metastasis in the surrounding tissues. Results: In the macrocarcinoma group, the proportion of patients with severe ELABELA staining (61.1%) was higher than that in the adenoma (50%) and microcarcinoma (23.8%) groups, while the proportion of those with mild to moderate staining was lower (p < 0.001). In the microcarcinoma group, the proportion of patients with severe staining was lower than that in the adenoma group, while the proportion of those with mild to moderate staining was higher (p < 0.001). In papillary thyroid carcinomas, the rates of moderate and severe staining in the classical variant, mild staining in the follicular variant, severe staining in the classical + follicular variant, and severe staining in the oncocytic variant were higher. Conclusion: To the best of our knowledge, this study is the first to be conducted on this subject. In this study, ELABELA was not found to be significant in the differential diagnosis of benign and malignant lesions of the thyroid gland. In papillary thyroid carcinomas, severe ELABELA staining patterns were more common in macrocarcinoma patients than in microcarcinoma patients.

The COL-4A1 polypeptide destroy endothelial cells through the TGF-β/PI3K/AKT pathway

“…Moreover an in vitro model suggested that GLP-1 improves the function of endothelial nitric oxide synthase (eNOS) to prevent or delay the formation of atherosclerosis in diabetes mellitus; study in Human umbilical vascular endothelial cells (HUVECs) showed that GLP-1 promotes angiogenesis 36 , 37 . The polypeptide ELABELA has become a research focus in many fields (hypertension, CVD, renal disease, thyroid gland disease and PE) in recent years, and the latest progress has supported and highlighted its therapeutic potential 38 , 39 . There is still a lack of research on the peptide COL-4A1 and PE, thus the current study is focused on exploring the association between COL-4A1 and PE ( Supplementary Information ).…”